Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial - Dummer, R; Brase, J C; Garrett, J (Lancet Oncol, 2020)
et al.